New York Times: Eli Lilly’s Antibody Trial Is Paused Over Potential Safety Concern
“A government-sponsored clinical trial that is testing an antibody treatment for Covid-19 developed by the drugmaker Eli Lilly has been paused because of a ‘potential safety concern,’ according to emails that government officials sent on Tuesday to researchers at testing sites. The company confirmed the pause…” (Wu/Thomas, 10/13).

Additional coverage of the trial’s pause is available from The Hill, POLITICO, STAT, and Wall Street Journal.